Srikanth Nagalla, MD

Srikanth Nagalla, M.D., is chief of benign hematology at Herbert Wertheim Cancer Institute. Dr. Nagalla specializes in treating benign (non-cancerous) hematological conditions, including bleeding and clotting disorders, rare blood disorders, high and low platelets, high and low blood counts, bone marrow failure syndromes and myeloproliferative neoplasms.

In addition to his extensive experience in benign hematology, Dr. Nagalla has a master’s degree in microbiology and immunology. He has also contributed significant research to the field of platelet biology that could have a lasting impact on how diseases are treated in the future. He has authored numerous peer-reviewed journal articles and book chapters in the field of hematology.

Dr. Nagalla joined Herbert Wertheim Cancer Institute from UT Southwestern Medical Center in Dallas, Texas. Throughout his career, he has served in multiple leadership roles.

Dr. Nagalla has a strong understanding of the pathophysiology of blood disorders, which is important when developing personalized treatment plans. It allows him to think outside of the box and provide treatment options that are most beneficial to his patients.

He believes in educating patients and their caregivers so they can serve as partners and advocates in the treatment process and experience better outcomes.

Dr. Nagalla is also passionate about training the next generation of physicians. He has received several awards for his work in teaching medical students and trainees. He serves on multiple national committees for medical education.

When he is not treating patients, Dr. Nagalla enjoys spending time with his family, traveling and golfing.